How are mathematical models and results from mathematical models of vaccine-preventable diseases used, or not, by global health organisations? by Christen, Paula & Conteh, Lesong
 1Christen P, Conteh L. BMJ Global Health 2021;6:e006827. doi:10.1136/bmjgh-2021-006827
How are mathematical models and 
results from mathematical models of 
vaccine- preventable diseases used, or 
not, by global health organisations?
Paula Christen,1 Lesong Conteh2
Original research
To cite: Christen P, Conteh L. 
How are mathematical models 
and results from mathematical 
models of vaccine- preventable 





Handling editor Seye Abimbola
 ► Additional supplemental 
material is published online only. 
To view, please visit the journal 
online (http:// dx. doi. org/ 10. 
1136/ bmjgh- 2021- 006827).
Received 6 July 2021
Accepted 15 August 2021
1Department of Infectious 
Disease Epidemiology, Imperial 
College London, London, UK
2Department of Health 
Policy, The London School of 
Economics and Political Science, 
London, UK
Correspondence to
Paula Christen;  
 paula. christen16@ imperial. 
ac. uk
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY. 
Published by BMJ.
ABSTRACT
While epidemiological and economic evidence has the 
potential to provide answers to questions, guide complex 
programmes and inform resource allocation decisions, 
how this evidence is used by global health organisations 
who commission it and what organisational actions 
are generated from the evidence remains unclear. This 
study applies analytical tools from organisational science 
to understand how evidence produced by infectious 
disease epidemiologists and health economists is used 
by global health organisations. A conceptual framework 
that embraces evidence use typologies and relates 
findings to the organisational process of action generation 
informs and structures the research. Between March 
and September 2020, we conducted in- depth interviews 
with mathematical modellers (evidence producers) and 
employees at global health organisations, who are involved 
in decision- making processes (evidence consumers). We 
found that commissioned epidemiological and economic 
evidence is used to track progress and provides a measure 
of success, both in terms of health outcomes and the 
organisations’ mission. Global health organisations 
predominantly use this evidence to demonstrate 
accountability and solicit funding from external partners. 
We find common understanding and awareness across 
consumers and producers about the purposes and uses 
of these commissioned pieces of work and how they 
are distinct from more academic explorative research 
outputs. Conceptual evidence use best describes this 
process. Evidence is slowly integrated into organisational 
processes and is one of many influences on global 
health organisations’ actions. Relationships developed 
over time and trust guide the process, which may lead 
to quite a concentrated cluster of those producing and 
commissioning models. These findings raise several 
insights relevant to the literature of research utilisation in 
organisations and evidence- based management. The study 
extends our understanding of how evidence is used and 
which organisational actions are generated as a result of 
commissioning epidemiological and economic evidence.
INTRODUCTION
In addition to domestic efforts, global health 
organisations (GHOs), such as the Bill & 
Melinda Gates Foundation and associated 
partnerships, such as the Global Alliance for 
Vaccines and Immunization, play a prominent 
Key questions
What is already known?
 ► Despite numerous initiatives to enhance knowl-
edge utilisation, the understanding of how burden 
of disease and vaccine impact estimates are used 
by global health organisations that commission re-
search evidence production is limited.
What are the new findings?
 ► Our study draws on an organisation science frame-
work to examine the role of burden of disease 
and vaccine impact estimates for global health 
organisations.
 ► We found that burden of disease and vaccine impact 
estimates are not directly translated into organisa-
tional actions but are used by global health organ-
isations to demonstrate accountability, to solicit 
funding and to get the buy- in from external partners.
 ► We found that evidence consumers can perceive ev-
idence as ‘negative’, if their entrenched knowledge, 
built up over time, is challenged, or if the evidence 
does not meet their expectations, thus impeding its 
use.
What do the new findings imply?
 ► Interactions between evidence producers and con-
sumers are vital so that evidence is produced in cor-
respondence to questions of evidence consumers.
 ► Commissioned models, global in their scope, appear 
to serve a specific purpose, distinct from other aca-
demic modelling efforts.
 ► Their value lies in their ability to track progress and 
thus advocate for resources.
 ► Is there a missed opportunity given their disconnect 
from national- level resource allocation decisions?
 ► Cocreating a research agenda may enhance evi-
dence consumers’ willingness to embrace model 
limitations and caveats thus allowing for more in-
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role in low and middle- income country (LMIC) immuni-
sation programmes.1 Donor assistance for health (DAH) 
from global, bilateral and multilateral partnerships and 
agencies targeting immunisation totalled $34.5 billion 
between 1990 and 2016,2 contributing to impressive 
health gains.3 4 Nonetheless, inequalities in the provision 
of universal immunisation for all children, as initially set 
out by the WHO in 1974 through the Expanded Program 
on Immunization, continue to exist between and within 
countries.5 These inequalities are even more pronounced 
in terms of access to COVID-19 vaccinations.6
In the effort to act on the impact of long- standing, 
emerging and re- emerging infectious diseases, GHOs work 
closely together with researchers by commissioning research 
projects that have the potential to solve complex problems.7–9 
Epidemiologists are commissioned by these organisations to 
estimate the impact of vaccines using mathematical models 
of infectious diseases. Epidemiological models can estimate 
the spread of infectious diseases in a given population and 
quantify the number of lives saved or deaths averted through 
public health interventions. Estimated number of deaths due 
to a disease can be used to inform other generic metrics (eg, 
disability- adjusted life years) to measure burden of disease 
and vaccine impact estimates (BOD & VIE) (eg, ref 10). The 
BOD was estimated under different vaccination coverage 
scenarios across 10 pathogens in 98 LMICs.10 This type of 
evidence has the potential to provide answers to policy ques-
tions,11 guide complex policy problems and inform resource 
allocation decisions.12–14
Despite numerous initiatives to enhance knowledge 
utilisation, the understanding of how BOD & VIE are 
used by GHOs is limited. Research utilisation studies have 
predominantly been conducted in other organisational 
contexts. Therefore, the objective of this study was to 
understand how BOD & VIE are used by the GHOs that 
commission the research and what actions are generated 
following the commissioning of evidence production.
METHODS
Study design and sampling
Research for this paper was informed by a conceptual 
framework, which addresses possible types of evidence 
use throughout different organisational processes.15 
The conceptual framework draws from organisation 
science, specifically Beyer and Trice’s literature review, 
which critically assessed the phenomenon of research 
utilisation in organisations systematically.15 We explic-
itly focus on the organisational process of action genera-
tion. Evidence use in the process of action generation is 
ascribed to three overarching categories of evidence use: 
instrumental, conceptual and symbolic.16 The typologies 
were initially proposed by Weiss17 and other pioneering 
scholars of knowledge utilisation.18–26 Instrumental use 
implies that a piece of research that presents BOD & VIE 
would directly influence a decision or act as a solution 
to a specific problem. Evidence use as such is systematic 
and a decision is traceable to a specific piece of research. 
Conceptual use of BOD & VIE follows a more complex 
process of knowledge translation, in which the research 
would indirectly impact the knowledge, understanding 
and/or attitude of the evidence receiver. This may lead to 
gradual changes in evidence receivers’ ways of thinking. 
Symbolic evidence use denotes research to be used more 
strategically. BOD & VIE would be drawn on to support 
a particular stance or to destabilise opposing positions. 
As such, BOD & VIE would be used anecdotally. Overall, 
evidence use models complement rather than contradict 
each other27 (table 1, online supplemental annex 1).
We conducted in- depth, semistructured interviews 
to explore how global BOD & VIE are used by GHOs 
as recommended by Hanney et al to study research 
utilisation.28
Beyer and Trice identify two main stakeholder groups in 
research utilisation: evidence producers and evidence consumers. 
For the purpose of this study, mathematical modellers 
commissioned to produce global BOD & VIE take up the 
role of evidence producers. Producers include individuals who 
work as epidemiologists or health economists at a research 
institution and who have extensive experience in the math-
ematical modelling of vaccine- preventable diseases. More-
over, they produce and disseminate BOD & VIE as academic 
outputs with the intent to inform decision- makers. Producers 
were initially identified as individuals, who are specialised 
in the mathematical modelling of a vaccine- preventable 
disease and were commissioned to produce the specific type 
of research evidence, global BOD & VIE by GHOs. Evidence 
consumers are employees at GHOs that commission research 
to, among other things, inform global resource allocation 
decisions and strengthen global immunisation systems 
through their organisational strategy. Consumers were initially 
identified by researching profiles of individuals employed at 
GHOs that grant funding to evidence producers and provide 
DAH to countries to support global vaccination initiatives. 
Evidence consumers do not have to be the final decision- 
makers but can sit along the pathway from receiving evidence 
to disseminating it to higher level decision- makers within 
the organisation (eg, board members taking organisation- 
wide decisions). This is important to note as previous studies 
have found that decisions are rarely made by a single indi-
vidual29 30 and individuals often do not regard themselves as 
ultimate decision- makers.31
We acknowledge that the line between evidence 
producers and consumers is blurred.32 Often, consumers 
may have taken the role of producers in previous occu-
pations or may even be evidence producers as part of their 
current position within their organisation. Therefore, 
we assign the informant to the organisation where they 
are employed at the time of the interview. We recognise 
that BOD & VIE may also be produced within the organ-
isations at which the evidence consumers are employed. 
For this reason, we specifically asked informants about 
the use of global BOD & VIE that were formally commis-
sioned to external constituencies.
Data were collected from purposively sampled individ-
uals between March and September 2020 by PC. Snowball 
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sampling was used to expand the study population to 
those who had not been identified previously but matched 
the outlined study eligibility criteria. Data saturation was 
achieved when ideas and/or opinions were repeated in 
different interviews. All interviews were conducted via 
the telecommuting software Zoom. Informed consent 
was obtained for every participant. A prewritten inter-
view guide with open- ended questions was used (online 
supplemental annex 2). Additional questions were asked 
to clarify any information or to go into further depth on a 
topic. PC held the position as informed ‘outsider’, which 
allowed to gain trust of and achieve rapport with study 
participants (online supplemental annex 3). Interviews 
were audiotaped from which intelligent verbatim tran-
scripts were produced. All study participants’ identities 
were pseudonymised to ensure confidentiality. Storage, 
organisation, searching and coding of transcripts were 
performed using NVivo V.12 Pro.33
In total, we approached 21 potential participants, 
2 individuals refused to participate and 6 individuals 
did not respond. Interviewees included seven evidence 
producers (epidemiologists (n=6), a health economist 
(n=1)) and six evidence consumers (senior programme 
officers (n=4), team lead of the department of immuni-
sation (n=1), medical epidemiologist in the department 
of immunisation (n=1)). All evidence producers held a 
position as postdoctoral fellow (n=3), assistant professor 
(n=2) or professor (n=2). Evidence consumers held a 
PhD (n=4), MSc (n=1), MPH (n=1) and/or MD (n=2). 
All interviewees were based in Europe (n=5) or North 
America (n=7), except for one evidence producer based 
in Asia.
Table 1 Summary of the definitions of explanatory models to evidence use
Instrumental
Instrumental evidence use describes the production and use of evidence in a linear process. This type of evidence use 
assumes the most rational approach.63 Scientific evidence is assumed to be instructive to the decision such that the impact 
is concrete and visible.64 Evidence use falls under the instrumental use category, when decisions are based on evaluation 
results.63
Knowledge- driven Problem- solving
 ► Evidence leads policy and decision- making.
 ► New technologies or innovations that result from scientific 
evidence are adopted by decision- makers.
 ► Evidence producers ‘push’ their evidence towards the 
decision- maker. As a result, new policies emerge.
 ► Evidence aims to reduce the decision- maker’s uncertainty 
around a specific problem by suggesting a specific 
solution.64
 ► Decision- makers consult evidence when needed (research 
antedates the problem), or evidence producers are 
commissioned by evidence consumers to find solutions to 
problems.64
 ► The policy goal is predetermined.64
Conceptual
Evidence influences actions, but in less specific, more indirect ways. Research evidence permeates the action generation.
Enlightenment Interactive
 ► Evidence use happens incrementally, leading to changes in 
the status quo in light of political realities as well as other 
factors and sources of evidence.
 ► Evidence may be used indirectly.64
 ► An advancement of the enlightenment model, giving rise 
to disorderly interconnections, networks and relationships 
among stakeholders to enable the understanding of 
different paradigms and viewpoints.
 ► Continuous back- and- forth among stakeholders.64
 ► Recognition of decision- making processes being 
complicated as stakeholders have different experiences 
with the evidence and diverging political insights, 
pressures and judgements.46
Symbolic
Evidence is used to legitimise and support existing positions of evidence users. Evidence is used as ammunition to support 
predetermined positions or to delay decisions strategically.
Tactical Political
 ► The evidence is not necessarily used as intended by its 
producer.17
 ► The fact that evidence is being produced is used 
as a supporting argument by organisations for their 
responsiveness towards an issue.
 ► The evidence consumer is uncontested and 
predetermined.65
 ► Evidence is used to support the decision- maker’s 
standpoint.
Adapted from Davies et al66 and Weiss17 and complemented with accounts from later publications.
BOD & VIE, Burden of disease and vaccine impact estimates; GHO, Global health organization.
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Analysis
The data were analysed using the framework method 
developed by Ritchie and Lewis,34 allowing for the 
comparison of predefined study population groups.35 
Emergent themes were identified through initial coding 
by the lead author, PC. The preliminary codebook was 
reviewed by the second author, LC. Next, initial coding 
was succeeded by focused, selective coding borrowing 
concepts from the theoretical framework following a 
deductive approach. This was spot- checked by the second 
author, LC. The information was aggregated by theme 
and subtheme with respect to the two predefined study 
population groups. The approach allows to explore the 
specific use cases of evidence, while leaving space to 
discover unexpected or further emerging themes and 
relate findings to organisational theories and processes.
Our results focus on how global BOD & VIE are used 
and what actions are generated by GHOs as a result of 
receiving this evidence, with respect to the research 
utilisation spectrum and associated explanatory models 
(table 1, online supplemental annex 1), and draw on key 
themes identified in the analysis.
Patient and public involvement
The design and conduct of the study, the development 




Instrumental evidence use describes the systematic 
production and use of evidence in a linear process, 
implying that BOD & VIE would directly influence a deci-
sion or act as a solution to a specific problem. In line 
with this interpretation, there was general agreement 
and criticism among evidence producers and consumers 
that the production of BOD & VIE is dictated by evidence 
consumers, who set out the research agenda explicitly by 
providing funding for specific types of evidence. Yet, no 
specific decisions made by GHOs could be traced to a 
specific piece of research.
Knowledge-driven model
For this model to apply, production of research evidence 
considered for use by evidence consumers should be 
driven by academic curiosity. Evidence producers and 
consumers agreed that this is rarely the case; however, 
opportunities exist for more of the processes along the 
evidence use route to be more knowledge driven.
Setting the research agenda
An evidence producer highlighted that evidence 
producers should lead the discussion on ‘what should 
be done’ that would be of value to evidence consumers. 
Thereby, the research agenda should be agreed on for 
each pathogen and for mathematical models of the same 
pathogen (ie, when having two or more mathematical 
models for one disease) (P1). The interviewee described 
the research agenda to be determined by evidence 
consumers:
We aren’t answering any questions about really what is actu-
ally happening at the policy level whether it is country- level 
policy and decision- making or global […] level decision- 
making. […], we are handed the demographics, we are 
handed the coverage assumptions and it is just running it 
through a population [pathogen] model, by age and time, 
to say what the impact of those assumptions would be. We 
are not really doing anything in terms of the research agen-
da. (P1)
Changes in evidence production
Evidence consumers and producers argued against the 
value of following the knowledge- driven route to evidence 
use. Informants stressed that changes in long- standing 
mathematical models can be a barrier to evidence use, as 
one evidence producer highlighted:
… for the most part, we are always a little cautious about 
dramatic changes in models because we’re really trying to 
translate observed changes in coverage, which is what [a 
GHO] has been investing in and understanding what that 
means for deaths averted [rather than] new modelling as-
sumption. (C1)
Furthermore, evidence producers (P2, P7) referred 
to the delicate balancing act of responding to specific 
commissions for prescribed global burden models, while 
also still trying to fund models driven by more personal 
academic interests linked to knowledge gaps and meth-
odological advances:
It’s sort of a little like a chicken and egg thing, I think. Like, 
you want to have those discussions, but […] I think, people 
don’t feel that they should give you the time or why would 
they give you the time if you haven’t done some work al-
ready? (P2)
There was a general agreement that a linear evidence 
production and consumption process, initiated by 
evidence producers, is rare and unrealistic given its reluc-
tance towards innovation and changes in evidence.
Problem-solving model
Interviewees addressed some principles of instrumental 
evidence use following the problem- solving model indi-
rectly through the process of commissioning evidence 
producers and setting out deliverables through contrac-
tual agreements.
Evidence use through the commissioning of research
Both evidence producers and consumers stressed that 
evidence production is led by evidence consumers as they 
are commissioning the evidence production. Thereby, 
the evidence consumer is viewed as a major influence on 
evidence production and determines its direction and 
organisation (C4). They predetermine research ques-
tions and become ‘technical agencies’ determining the 
research agenda, as one interviewee stated:
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When you, as an academic institute get funding, you will 
not argue with your donors, which are funding you. So, you 
follow the donor, you follow the money. […] [The funding 
organizations] are not only funding, they are doing more 
and more technical assistance, they are very much involved 
in the model set up, in everything from contracting to im-
plementing. (C4)
An evidence producer also raised concern about the 
fact that the research agenda and problem definition 
is led and decided on by evidence consumers. While 
progress, goals and activities are discussed, grant deliv-
erables that define the research agenda are set ex ante 
(P7). Evidence producers and consumers stated that this 
ignores the expertise of the evidence producer, who is 
arguably more aware of what requires further research 
(P2, C4). However, an evidence producer highlighted 
that commissioned research should be the result of discus-
sions for the evidence to be ‘usable’ to decision- makers:
I’d say that the questions need to be applicable, usable, 
and so [the decision- makers] very much should be in the 
discussion of setting those questions. (P6)
It is evident that the interviewee sees value in more 
interaction between actors, also reflected in the interac-
tive model (section Interative Model).
Problem definition
Questions posed by decision- makers when commissioning 
research may not necessarily be the ‘right’ questions 
or lead to decisions that are ‘right’ (P2). An evidence 
producer raised concerns that aggregating the impact 
of all mathematical models and projecting results to a 
global scale limits sufficient attention on specific national 
and subnational questions. For example, assumptions 
that all children who have received a first vaccine dose 
are also administered the second vaccine dose if required 
can lead to misleading outcomes (P1).
Conceptual evidence use
In this next subsection, we explore the extent evidence 
permeates actions in more indirect ways leading to incre-
mental changes in knowledge, understanding and/or 
attitude of evidence consumers as a result of using BOD 
& VIE.
Enlightenment model
According to informants, evidence influences the organi-
sational agenda incrementally over time. Which vaccines 
drive the most impact is ingrained in people’s knowledge 
as estimates have been seen many times (C2):
Our management isn’t using the numbers in a one- to- one 
way to make trade- offs. But it’s more that this is really foun-
dational information for us to understand what the most 
important areas for us are to invest in. And then that drives 
more on an underlying fundamental basis, what we invest 
in immunizations. (C2)
Another evidence consumer highlighted that the 
evidence is not used by decision- makers at a high level 
to understand details of the impact of pathogen- specific 
interventions that are modelled mathematically (eg, 
which age groups are affected or the specific immunity 
gaps within countries) (C5).
Further, investment decisions made by an organisa-
tion’s management affect the work of all other depart-
ments within the organisation (C2):
So [BOD & VIE are] not the only thing that we would fac-
tor in, but it would be something that helps us to prioritize 
which countries we will most focus on investing in. And 
then that trickles down to all the rest of our work. (C2)
Therefore, research evidence shows to be ‘creeping’ 
into decisions, which is consistent with principles of the 
enlightenment model to evidence use. The applicability 
of the enlightenment model is further discussed under 
specific subthemes.
Argument-generating evidence
A subtheme applied to the enlightenment model to 
describe evidence use is that evidence has often been 
argument generating. The interviews conducted for this 
study highlighted several argument- generating questions 
oftentimes asked by evidence consumers after receiving 
BOD & VIE. Recurring questions were extracted from 
the interview data (box 1). The argument- generating 
component in the evidence use route suggests that social 
interaction is a sine qua non to facilitate evidence use for 
action generation (further discussed in section Interactive 
Model). If the evidence does not support the evidence 
consumer’s belief, and questions (eg, those in box 1) 
remain unanswered, the evidence consumer believes that 
the evidence is the problem (C6).
As of interviewees’ accounts, the dissemination of 
BOD & VIE is often formally set out through reporting 
channels. This challenges the applicability of the enlight-
enment model, which defines the route of evidence 
permeation to be unguided and indirect. Tools to dissem-
inate evidence suggest a guided evidence use process; 
however, the understanding of evidence cannot always 




Social interaction allows evidence to be produced with 
reference to what evidence consumers need to know in 
an iterative process (C4). Therefore, evidence consumers 
should be included in the early stages of the evidence 
development, including the set- up of the model structure 
and defining the outcomes that are required (C4, C5). 
Further, social interactions are required to answer the 
questions (eg, those in box 1).
Evidence producers and consumers have highlighted 
that interactions are required to ensure understanding of 
what can be researched, inherent limitations and caveats 













ealth: first published as 10.1136/bm






6 Christen P, Conteh L. BMJ Global Health 2021;6:e006827. doi:10.1136/bmjgh-2021-006827
BMJ Global Health
Moreover, interactions through long- standing rela-
tionships reduce disruptiveness when the evidence 
changes over time, especially if conclusions are different 
from previous ones, leading to a shift in resource allo-
cations (P7, P3). Changes in mathematical models and 
evidence supplied to consumers were viewed as a major 
point for discussion in interactions between evidence 
producers and consumers. Foundational knowledge, 
which has entrenched within evidence consumers over 
time, is being challenged, if new evidence does not meet 
its consumers’ expectations (P4). A lack of relationships 
may lead to challenges when trying to get the buy- in from 
stakeholders to use the evidence (P7, P2).
Overall, there was a consensus among evidence 
producers and consumers that the interactive model 
should define the route to evidence use. However, this 
model cannot necessarily be used to explain the current 
evidence use at stakeholders’ organisations. Interactions, 
especially at an early stage of evidence production, are 
required specifically for ensuring that evidence and its 
limitations and caveats are understood to promote its use 
and avoid evidence consumers ignoring it.
Symbolic evidence use
Under the symbolic evidence use category, which stands 
in stark contrast with instrumental evidence use, evidence 
is used in a strategic manner for decisions that have 
already been taken. The symbolic use identified in this 
study aligns with the political explanatory model, that 
is, evidence is used to support the evidence user’s stand-
point. No respondents spoke of the tactical model where 
solely the fact that research is being conducted is used in 
evidence users’ actions.
Political model
An evidence consumer interviewee refers to ‘meta- 
questions’, which should be addressed by evidence 
producers (C5):
But [evidence producers are] answering kind of a more 
existential question rather than a specific programmatic 
question. (C5)
Probing revealed that evidence from mathematical 
models is mainly used for strategic thinking, planning 
purposes (C3), accountability and advocacy purposes 
when engaging with external funding partners of 
evidence consumers (C1, P6). BOD & VIE are used to 
solicit funding for further rounds of funding from donor 
partners (C1):
The impact numbers are probably the most important 
numbers that we use for replenishment efforts and for re-
porting to donors, so for high- level kind of accountability. 
(C1)
Sometimes, evidence is used for framing the setting or 
as contextual information for anyone trying to make the 
case for why the organisation should invest in a particular 
project over another one (C2). Evidence on vaccine 
impact comes into play when someone needs supporting 
evidence for his/her argument (C2) or to track the 
organisations’ progress (C5).
An evidence producer stated that despite estimates 
from multiple models for the same pathogen being hugely 
different, the main conclusions remain (P4). Details on 
BOD & VIE are of less interest to evidence consumers 
(C4). Rather, evidence consumers are interested in the 
direction of impact to support his/her argument (C4).
Overall, the political model describes evidence use 
once the evidence is engrained in the decision- makers’ 
understanding and the organisation’s agenda. Evidence 
consumers agree that research evidence is often used 
to inform and communicate targets to donors and to 
support an argument when wanting to receive more 
funding. Evidence producers did not provide any infor-
mation alluding to the applicability of the political model.
DISCUSSION
This paper set out to examine how one type of commis-
sioned research evidence (global BOD & VIE) is used 
by GHOs that aim to strengthen global immunisation 
systems. The findings highlight that BOD & VIE are not 
Box 1 Argument- generating questions oftentimes posed 
by evidence consumers after receiving burden of disease 
and vaccine impact estimates (BOD & VIE)
 ► What are the mathematical model differences in comparison to the 
previous year or reporting period? (C3)
 ► How well has the model done at predicting things that we know 
have happened in the past? Why are model estimates not meeting 
the consumers’ expectations? Can estimates be trusted? (P4)
 ► What explains changes in the mathematical model which affect the 
estimated impact? (C3, C1)
 ► Do we believe that these are good changes or are they going to 
end up going the other direction the next year when the modellers 
update their assumptions again? (C1)
 ► Is a change in BOD & VIE the result of something that happened in 
the world? Did the coverage decrease? Did the production not hap-
pen? Did something in the model change? Did the understanding of 
the epidemiology of a pathogen evolve? (C2)
 ► What drives differences in impact estimates from different models? 
(C3, C2)
 ► Are the multiple models valid for the same pathogen? Is there an 
error in one of the models? (C2)
 ► What can models do and cannot do? What improvements may be 
needed? With the aim of eliminating specific diseases, how does 
the mathematical model need to be aligned or changed? (P1)
 ► What is the population- level impact that goes beyond direct pro-
tection (herd immunity effect) in lower income settings where data 
are limited? (P5)
 ► How can estimates be additive in terms of not just using them in 
a vacuum, but using them to better understand and validate admin 
data estimates that come out? (C5)
 ► How do you interpret the relative contribution of different source 
of vaccination to the overall burden? That is, routine immunisation 
programmes (multiple doses), pulse national campaigns or national 
or subnational campaigns, outbreak response. (P3)
 ► What are the assumptions around the treatment for a disease? (C1)
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directly translated into GHOs’ actions, that is, systemat-
ically translated into vaccine resource allocation deci-
sions, but are used to demonstrate accountability and 
solicit funding from external partners. While GHOs’ 
actions are partially influenced by BOD & VIE, the 
evidence is mainly used anecdotally. With regard to the 
conceptual framework used to analyse the results, the 
conceptual model and the political model best describe 
how evidence is used by GHOs.
Previous studies have furthered our understanding 
of evidence use by individuals, national governments 
and organisations on a variety of public health policies 
and decisions, such as maternal and child health36 and 
drug policies.37 However, to our knowledge, this is the 
first study to focus on the use of global epidemiological 
and economic research commissioned by GHOs using an 
organisational science perspective.
GHOs operate in a highly competitive environment.38 39 
While international organisations receive support based 
primarily on the extent to which they can fulfil their 
mandate, philanthropic organisations’ funds are not 
dependent on support from donor partners.40 In this 
sense, the use of BOD & VIE is threefold. First, BOD & VIE 
are used to validate GHOs’ short- term funding objectives 
by comparing estimates with coverage data. Second, the 
evidence is used for strategically planning organisational 
mid- term to long- term actions by reflecting on the poten-
tial global health impact of their investments. Third, BOD 
& VIE are used to garner financial support from donor 
partners to pursue these objectives. These donor part-
ners formally assess the impact of their budget allocation 
to international organisations through initiatives such as 
the Multilateral Organizations Performance Assessment 
Network.38 This explains GHOs’ high financial commit-
ment towards commissioning research evidence in the 
form of global BOD & VIE, which demonstrates and 
markets the organisations’ impact, thus helping secure 
buy- in from their donor partners.
BOD & VIE also come into play when someone requires 
supporting evidence for their argument within the organ-
isation. GHOs are ‘political’ organisations, in which 
several potentially conflicting interests and stakeholder 
groups exist.38 For this reason, BOD & VIE are used to 
promote a division’s cause internally. For example, BOD 
& VIE have been used to support internal decisions on 
why to invest in one vaccine over another.
Research evidence use by GHOs happens over a 
prolonged time in which many people within the organ-
isation learn about the evidence. Over time, evidence on 
disease burden and vaccine impact becomes ingrained 
in people’s knowledge. From organisational theory, 
we learn that organisational norms and objectives are 
entrenched in employees’ minds.41 42 Actions are admix-
tures of scientific evidence and non- rational prem-
ises.43 Organisations’ actions embrace the ideas of their 
founders. Stinchcombe highlights that values are often 
preserved, and interests are protected by those who 
possess and retain power.44 With respect to this explicit 
role of agency and power within GHOs, BOD & VIE 
compete with other factors influencing organisational 
decisions. We found that organisational actions follow 
preset pathways established by executives’ opinions, 
interests and organisational norms rather than BOD & 
VIE forging new paths. As a result, we suggest further 
research into whether and how GHOs benefit from the 
accumulated knowledge, experiences and learnings of 
their employees. Further empirical research on organ-
isational learning processes as suggested by Langley45 
was beyond the remit of this research, in part to protect 
respondents’ confidentiality.
This study showed that, unsurprisingly, open interac-
tions between evidence consumers and producers are vital 
to facilitate understanding of the evidence and its caveats 
and limitations.46–48 We found that evidence consumers’ 
questions, which set the research agenda, are not neces-
sarily preview to or shaped by evidence producers. 
Previous studies suggest that evidence consumers, who 
participate in earlier phases of research, react favourably 
to results.49 However, rather than evidence consumers 
prescribing the research agenda, we found agreement 
among respondents that the problem definition should 
result from dialogues between evidence producers and 
consumers. To facilitate these dialogues and to enable 
the reflection of societal concerns, Beran et al advocate 
for platforms for exchange and the institutionalisation of 
a multistakeholder approach.50
Consistent with findings of previous studies, our study 
showed that trusted relationships can lead to trust in 
evidence and the acceptance and adoption of new 
evidence, which may otherwise be regarded as contro-
versial or ‘negative’ evidence.51–53 This may be the case 
if foundational knowledge, which has entrenched within 
evidence consumers over time, is being challenged, 
not meeting their expectations. Early organisational 
studies showed that ‘negative’ research evidence can 
actively threaten the beliefs and worldviews of evidence 
consumers.15 54 All evidence consumers interviewed for 
this study had extensive prior education in infectious 
disease epidemiology, yet they were still reluctant to use 
findings from commissioned BOD & VIE, if these devi-
ated too far from previous BOD & VIE or strongly held 
beliefs. Therefore, our study shows that organisational 
norms, objectives and/or other factors prevail direct, 
demonstrable use of evidence in this context.
While the benefits of interactions among evidence 
producers and consumers became obvious through this 
and other research, this process can also jeopardise the 
objectivity of the scientific community. The objectivity of 
the scientific community may be questioned if the polit-
ical interests of research commissioners inhibit knowl-
edge production. While this was not voiced by evidence 
consumers or producers interviewed for the purpose of 
this study, evidence- informed decision- making interven-
tions that aim to enhance the dialogue between stake-
holders need to reflect on the role of power and politics 
in the process of knowledge production.55
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Mathematical models of infectious diseases have 
increasingly gained attractiveness among global health 
actors as they complement other epidemiological studies 
(eg, clinical trials56) and are less cost- intensive. They allow 
testing scenarios relatively quickly, while not being prone 
to the same ethical concerns. Despite inherent caveats 
and limitations of mathematical models, they provide 
high- level perspectives on global matters. As with other 
types of evidence, BOD & VIE should always be presented 
with underlying uncertainties and caveats.57 Our study 
suggests both producers and consumers share an honest 
assessment and understanding of the underlying uncer-
tainties and caveats of mathematical models. Yet, when 
communicating results to external constituencies (eg, 
donor partners), point estimates are used to simplify 
messages and the important aspect of uncertainty is lost. 
This further supports our conclusion that evidence is 
used anecdotally when mobilising resources from donor 
partners, thereby serving a strategic purpose.58
Despite the growing number of organisations and actors 
in the global health system, it is strongly influenced by 
only a few entities that are headquartered in high- income 
countries,59 the Global North. As this study shows, math-
ematical models are predominantly used to demonstrate 
accountability by quantifying their impact and to proof 
organisations’ legitimacy to solicit funding from external 
partners. We acknowledge that the focus of this study has 
been a specific type of knowledge output commissioned. 
Other types of research, which are more explorative, 
innovative and less prescribed, and evidence produced by 
researchers from the Global South contribute differently 
to organisational actions taken. What the portfolio of 
evidence drawn on by GHOs embraces and how evidence 
use compares across this portfolio should be subject for 
further research. Moreover, this study focused on the use 
of evidence by philanthropic organisations or organisa-
tions with procurement mandates. Thus, the findings 
may not be fully transferable to the utilisation of BOD & 
VIE by advisory GHOs (eg, WHO), where such evidence 
may be used to give strategic and rapid guidance.
Limitations
This study has its limitations. First, study participants’ 
responses may have been subject to social desirability. 
Both parties may have voiced their idealistic evidence use 
rather than the actual evidence use. Second, interviews 
were meant to have been conducted in person. Sometimes, 
it was difficult to grasp participants’ voices, opinions and 
non- verbal communication via video calls. However, this 
method of collecting primary data is considered a viable 
alternative to conducting interviews face to face.60 Third, 
the study relied on a small sample size and only reflected 
the view of a small proportion of employees of GHOs that 
commission evidence and researchers. However, given 
the highly concentrated nature of stakeholders operating 
at this global level of vaccine resource allocation, find-
ings are likely to be qualitatively robust with regard to 
the sampled institutions. Lastly, all evidence producers 
and consumers were affiliated with an institution in a 
high- income country. Findings of this study may not 
reflect how evidence produced by evidence producers 
affiliated with academic institutions in LMICs is used by 
GHOs based in LMICs or local government bodies. We 
suggest this to be subject for further research. While our 
sample is a reflection of those most involved in this type 
of evidence production and consumption, it speaks to 
the perils of the ‘foreign gaze’ and ‘entrenched power 
asymmetries in global health partnerships’ that are being 
increasingly challenged by many of our respondents and 
the wider literature.61 62
CONCLUSION
In conclusion, we found GHOs use BOD & VIE to 
demonstrate impact and accountability at the global 
level, often to solicit funding to support global immuni-
sation efforts. GHOs that commission research evidence 
production and consider using research evidence should 
be engaged continuously throughout the research 
production process to maximise the value of BOD & VIE. 
Similarly, evidence producers should be engaged when 
GHOs use their research products. BOD & VIE are used 
to convince others of organisational legitimacy and may 
have had a direct influence on national, subnational and 
local vaccine resource allocation decisions. Yet, global 
BOD & VIE have been underused and only impacted 
GHOs’ actions indirectly. Arguably, global BOD & VIE 
have greater potential and can lead to more informed 
organisational actions, such as guiding vaccine resource 
allocation decisions across countries, not only to track 
progress and measure organisational success.
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How are mathematical models and results from mathematical models of vaccine-preventable 
diseases used, or not, by global health organizations? 
 
Theoretical orientation 
Our analytical approach draws on key concepts of knowledge utilization. Given the vast number of 
studies, we only provide a brief account of the key theoretical and empirical findings and concepts 
relevant to this study and which underpin our assumptions.  
Research utilization, a term used interchangeably with knowledge translation and research uptake has 
been studied in various disciplines. The individual decision-making process (i.e. at the micro level) has 
been mostly tackled by research psychologists (e.g. (1)), while decisions taken concerning national and 
international policies (i.e. the macro level) have been studied by political scientists (e.g. (2)). Finally, 
research utilization by organizations (i.e. the meso-level) has largely been the concern of organization 
and management scientists (3). 
Research utilization by organizations aligns with the study of evidence-based management (EBM). 
EBM is derived from the model of evidence-based medicine and evidence-informed policymaking (4). 
A rich pool of literature has emerged around the use of evidence in different health settings over the 
past three decades. Existing studies predominantly focus on evidence use by physicians (5), managers 
of healthcare facilities and decision-makers who are directly involved in policymaking (6).   
The framework presents findings from empirical research on a spectrum of research utilization 
typologies and relates these findings to organizational processes. Beyer and Trice’s framework 
encompasses four organizational processes: information processing, affective bonding, strategy 
formulation and control, and action generation. Information processing concerns the cognition of 
research through deliberate actions of sensing, searching and diffusing evidence. Affective bonding 
refers to evidence consumers’ feelings about research. Evidence consumers’ affective reaction, 
receptivity and commitment towards evidence use shape this organizational process. The 
organizational process of strategy formulation and control addresses behaviours following the 
recognition of research evidence by selecting, evaluating and providing feedback on research 
evidence. Action generation pertains to the adoption, use, and, sometimes, the institutionalization of 
evidence (7). In previous analyses, scholars have set their focus on one of these organizational 
processes.  
Instrumental evidence use follows a rational, prescriptive and systematic approach (8). Research is 
directly used in direct and specific ways (9). Either, questions identified by an organization lead to the 
commissioning of research to find a solution (problem-solving/engineering/policy-driven model) (10), 
or, research initiates organizational actions (classic/purist/knowledge-driven model) (9,11). The latter 
model is inherent to the assumption that stakeholders have a consensus on a goal and that evidence 
is sought and used actively in policy and decision-making processes (12).  
Figure 1 Spectrum of knowledge utilization and associated explanatory models as conceptualized by Weiss (56,57) 
Organizational process: action generation 
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Within the category of conceptual evidence use, potential evidence users consider multiple sources 
of evidence and other contextual factors influence actions (9). This reflects the complexity of 
organizational processes arguably more realistically (13). Evidence production and consumption are 
therefore not bound to a linear, but a dynamic process. Conceptual evidence use can be described 
with the enlightenment (9) or the interactive model (11). In the enlightenment model evidence 
‘creeps’ into decisions, shaping them incrementally over a longer period (14). The interactive model 
in this category of evidence use is defined similarly to the enlightenment model. Though, this model 
focuses more specifically on the existence of collaborations among stakeholders (12). 
Lastly, symbolic evidence use can be further described through the political model or the tactical 
model (11). In the political model, evidence is used as a supportive device for a position that has 
already been taken. Organizations use evidence selectively and strategically. In the tactical model, the 
content of the evidence is negligible as the fact that research is being conducted in the field is used as 
an argument. Assumptions, in-depth explanations, critics and examples of each of the explanatory 
models were further outlined by Case (13). Variations of the six explanatory models are described by 
Hanney et al (11). 
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Semi-structured interview questions 
 
The interview guide was designed with reference to publicly available semi-structured interview 
guides from similar studies (28,74) as well as the theoretical framework by Beyer and Trice (Error! 
Reference source not found.).   
The following questions will be chosen depending on the profession of the study participant.  
 
 What is your involvement in vaccine resource allocation decisions?  
 What are the responsibilities regarding the work that you are reporting to the VIMC 
or that you are producing for the VIMC?  
 How do you think are your estimates being used to inform policy and decision 
makers regarding the allocation of resources? 
 In the case of receiving diverging information on the same matter, how is the 
information used in your [model/decision]?  
 Is there a measure of quality control of information or knowledge shared with you?  
 What is your experience when engaging with policy and decision makers?  
 How do questions posed by policy and decision makers impact the design of your 
mathematical model?  
 What initiated you designing the mathematical model that has been used to inform 
the VIMC?  
 Have you received feedback about your mathematical model from policy and 
decision makers? What was the feedback? Have you amended your work 
respectively? If so, who?  
 Have you received feedback about your mathematical model from the VIMC? What 
was the feedback? Have you amended your work respectively? If so, who?  
 How you are engaging with other individuals acting upon vaccine resource allocation 
decisions? 
 What is the intensity of engagement between you and other stakeholders who are 
acting upon vaccine resource allocation decisions is? Who are other stakeholders, 
who you are working with?  
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 How do you aim to answer questions by policy and decision makers using 
mathematical models? 
 How are model results and estimates explained to resource allocation decision 
makers? 
 How are mathematical models scoped and tailored to specific questions by policy 
and decision makers? 
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Reflexivity statement 
PC conducted all interviews and conceptualized this study. She held the position as an informed 
“outsider” (1) with a background in epidemiology, economics and management science. She was 
therefore familiar with the technical terminology of both the evidence producers and consumers. 
Additionally, this background provided PC with an awareness of potential areas of sensitivity when 
probing on internal organizational actions and processes.  
However, the interviewer’s experience in the mathematical modelling of infectious diseases as well as 
in the conducting of research to support policy- and decision-makers allowed her to easily establish 
rapport and gain the trust of interviewees. Both, evidence producers and consumers were receptive 
and cooperative throughout the data collection process, and expressed confidence that their 
reflections on the use of evidence by global health organizations would be accurately understood and 
represented by the interviewer. By holding a ‘shared experience’ position with evidence producers, 
the interviewer had the ability to ask relevant follow-up questions and diminish distance during 
interviews. Furthermore, this position allowed her to comprehend implied content when analyzing 
the data. This was evident in interviewees’ expressions, such as “you know…” and leaving sentences 
unfinished, implying interviewees had prior knowledge of the researchers’ background.  
Additionally, the interviewer’s background in management science allowed her to develop a codebook 
that was informed by the conceptual framework developed by Beyer and Trice (2). Her prior 
knowledge of organizations’ cultures and mathematical modelling of vaccine-preventable diseases 
allowed the author to highlight sub-themes and dive into specific organizational processes as well as 
subordinate questions around BOD & VIE in the analysis. This benefited the data collection as well as 
analysis as it shaped the thematic scope of the research, complementing the themes of the conceptual 
framework. 
Yet, the interviewer had not worked at a global health organization classified as a philanthropic 
organisation or organisations with procurement mandates. This led the researcher to ask clarifying 
questions that focused on specific processes that had not necessarily been shared on organizations’ 
websites or been explained in the literature. This benefitted the data analysis as evidence consumers 
answered questions with a lot of detail.  
The researchers are aware of the risks when research is conducted by an informed “outsider”, such as 
imposing own beliefs and perceptions by the researcher and the possibility of projecting biases (3). 
The review of the semi-structured interview guide (Annex 2) as well as the codebook by the second 
author, LC, aimed to reduce the possibility of introducing these biases and ensured an objective data 
analysis as the perspectives of two researchers were triangulated. Similarly, the second author was 
engaged in the data analysis by critically reviewing whether statements by evidence producers are 
clear enough to someone with no prior knowledge of infectious disease modelling. In cases where the 
interview content was unclear or ambiguous due to the use of technical terminology or the 
assumption that the authors had full understanding of the topic, the interviewee was contacted to 
clarify the argument. Through this approach, the authors aimed to reduce the danger of participants 
withholding information they assumed to be obvious to the researchers (1).  
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